CalciMedica (NASDAQ:CALC), Inc. is a clinical‐stage biopharmaceutical company headquartered in La Jolla, California, dedicated to developing novel therapies for acute cardiovascular and renal diseases. Founded in 2002, the firm has built its expertise around targeting key inflammatory pathways implicated in organ injury. Through a combination of proprietary antibody technologies and small‐molecule inhibitors, CalciMedica seeks to address high‐unmet‐need conditions such as acute kidney injury, ischemia‐reperfusion injury and acute necrotizing pancreatitis.
The company’s lead product candidate, CR002, is a fully human monoclonal antibody designed to neutralize high mobility group box 1 (HMGB1), a protein released during tissue injury that drives harmful inflammation. CR002 is being evaluated in multiple clinical settings, including acute kidney injury and acute coronary syndrome, with initial data suggesting a favorable safety profile and promising pharmacodynamic effects. In parallel, CalciMedica is advancing CR006, an innovative small‐molecule inhibitor targeting the p38 MAP kinase pathway, in preclinical studies aimed at reducing reperfusion injury following cardiac events.
CalciMedica conducts its research and development activities primarily in the United States, with strategic collaborations and trial sites extending into Europe and Asia. The company maintains partnerships with leading academic medical centers to facilitate translational research and expedite clinical proof‐of‐concept studies. Its in‐house team oversees chemistry, manufacturing and controls (CMC), as well as preclinical toxicology, ensuring alignment with regulatory expectations throughout the drug development process.
Under the leadership of an experienced executive team and board of directors, CalciMedica emphasizes rigorous clinical development and regulatory strategy to advance its pipeline toward commercialization. Leveraging decades of combined experience in pharmaceutical development, the organization is focused on forging industry partnerships to support late‐stage trials and eventual product launch, with the goal of delivering new treatment options for patients facing life‐threatening acute inflammatory conditions.
